Table II.
Reversal effect of Icory on HepG2/ADM, MCF-7/ADR and their parental sensitive cells.
| Treatments | IC50 ± SDa (μM) (fold-reversalb)
|
|||
|---|---|---|---|---|
| HepG2/ADM | HepG2 | MCF-7/ADR | MCF-7 | |
| DOX | 78.5314±9.7768 (1.00) | 0.3357±0.0193 (1.00) | 27.9157±0.8581 (1.00) | 0.1921±0.0184 (1.00) |
| + Icory 25 μM | 9.3748±0.6148 (8.38) | 0.3728±0.0467 (0.90) | 13.8451±0.5140 (2.02) | 0.1373±0.0064 (1.39) |
| + Icory 50 μM | 2.5256±0.6897 (31.09) | 0.3653±0.0849 (0.92) | 2.6711±0.6350 (10.45) | 0.1913±0.0414 (1.00) |
| + VRP 50 μM | 1.1914±0.2304 (65.92) | 0.3639±0.1987 (0.91) | 0.6437±0.1536 (43.37) | 0.1837±0.0415 (1.05) |
| VCR | 5.6795±0.6825 (1.00) | 0.0125±0.0018 (1.00) | 6.4485±3.7066 (1.00) | 0.0035±0.0013 (1.00) |
| + Icory 25 μM | 0.3408±0.2562 (16.67) | 0.0128±0.0019 (0.97) | 5.0590±1.3830 (1.27) | 0.0043±0.0003 (0.82) |
| + Icory 50 μM | 0.1384±0.0988 (41.04) | 0.0132±0.0030 (0.94) | 0.0110±0.0083 (584.10) | 0.0040±0.0014 (0.88) |
| + VRP 50 μM | 0.0037±0.0001 (1525.93) | 0.0132±0.0001 (0.94) | 0.0024±0.0016 (2633.12) | 0.0026±0.0007 (1.34) |
| Paclitaxel | 10.7748±2.2922 (1.00) | 0.0222±0.0154 (1.00) | 15.7079±2.6061 (1.00) | 0.0093±0.0071 (1.00) |
| + Icory 25 μM | 0.6820±0.3245 (15.80) | 0.0247±0.0008 (0.90) | 7.7363±0.7618 (2.03) | 0.0095±0.0012 (0.98) |
| + Icory 50 μM | 0.1462±0.0585 (73.70) | 0.0227±0.0034 (0.98) | 0.0467±0.0118 (336.36) | 0.0093±0.0009 (1.01) |
| + VRP 50 μM | 0.0105±0.0024 (1029.11) | 0.0207±0.0054 (1.07) | 0.0033±0.0010 (4783.16) | 0.0100±0.0013 (0.93) |
| Cisplatin | 26.9154±0.08765 (1.00) | 20.7555±0.5778 (1.00) | 25.0096±1.2170 (1.00) | 22.0492±1.0443 (1.00) |
| + Icory 50 μM | 26.0751±0.6919 (1.03) | 23.4144±3.5658 (0.87) | 20.6873±3.1638 (1.21) | 18.7218±6.9056 (1.18) |
| + VRP 50 μM | 23.0622±0.0826 (1.17) | 22.8127±1.4291 (0.91) | 29.4822±3.2336 (0.85) | 21.0994±4.1638 (1.05) |
a
Data in the table are shown as means ± SD of three independent experiments performed in six replicates.
b
The fold-reversals are calculated as IC50 for cells with the anticancer drugs in the absence of inhibitors divided by that in the presence of inhibitors.